- Home
- PCRX vs NDMO Comparison
PCRX vs NDMO Comparison
Compare PCRX & NDMO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCRX | NDMO |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 604.7M |
| IPO Year | 2010 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PCRX | NDMO |
|---|---|---|
| Price | $23.45 | $10.01 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $37.60 | N/A |
| AVG Volume (30 Days) | ★ 796.4K | 113.1K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | N/A |
| EPS | ★ 0.16 | N/A |
| Revenue | ★ $541,533,000.00 | N/A |
| Revenue This Year | $7.10 | N/A |
| Revenue Next Year | $9.15 | N/A |
| P/E Ratio | $146.94 | ★ N/A |
| Revenue Growth | ★ 26.04 | N/A |
| 52 Week Low | $18.80 | $9.30 |
| 52 Week High | $27.99 | $10.82 |
Technical Indicators
Market Signals| Indicator | PCRX | NDMO |
|---|---|---|
| Relative Strength Index (RSI) | 57.50 | 35.19 |
| Support Level | $22.57 | $9.94 |
| Resistance Level | $23.91 | $10.43 |
| Average True Range (ATR) | 0.91 | 0.16 |
| MACD | 0.08 | -0.04 |
| Stochastic Oscillator | 80.61 | 7.66 |
Price Performance
Historical ComparisonAbout PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About NDMO Nuveen Dynamic Municipal Opportunities Fund of Beneficial Interest
Nuveen Dynamic Municipal Opportunities is a closed-end management investment company. Its investment objective is to seek total return through income exempt from regular federal income taxes and capital appreciation. A majority of its investments are made in municipal securities, the income from which is exempted from regular federal income taxes.